Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non Operating Income (2016 - 2022)

Historic Other Non Operating Income for Enanta Pharmaceuticals (ENTA) over the last 11 years, with Q2 2022 value amounting to $393000.0.

  • Enanta Pharmaceuticals' Other Non Operating Income fell 1047.84% to $393000.0 in Q2 2022 from the same period last year, while for Jun 2022 it was -$782000.0, marking a year-over-year increase of 7863.97%. This contributed to the annual value of -$27000.0 for FY2021, which is 11812.08% down from last year.
  • As of Q2 2022, Enanta Pharmaceuticals' Other Non Operating Income stood at $393000.0, which was down 1047.84% from $255000.0 recorded in Q1 2022.
  • Enanta Pharmaceuticals' Other Non Operating Income's 5-year high stood at $2.4 million during Q2 2019, with a 5-year trough of -$5.3 million in Q3 2020.
  • Moreover, its 5-year median value for Other Non Operating Income was $393000.0 (2022), whereas its average is $222800.0.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first crashed by 11515.15% in 2018, then skyrocketed by 2405000.0% in 2019.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Other Non Operating Income stood at -$100000.0 in 2018, then skyrocketed by 2176.0% to $2.1 million in 2019, then plummeted by 67.39% to $677000.0 in 2020, then plummeted by 61.89% to $258000.0 in 2021, then surged by 52.33% to $393000.0 in 2022.
  • Its Other Non Operating Income stands at $393000.0 for Q2 2022, versus $255000.0 for Q1 2022 and $258000.0 for Q4 2021.